Hologic, Inc.’s Stock Price Dips to $75.11, Marking a 3.13% Decrease: Is it Time to Buy?

Hologic, Inc. (HOLX)

75.11 USD -2.43 (-3.13%) Volume: 1.76M

Hologic, Inc.’s stock price currently stands at 75.11 USD, experiencing a dip of -3.13% in the latest trading session, with a trading volume of 1.76M. Despite the recent drop, the HOLX stock maintains a positive year-to-date performance, showcasing a growth of +5.12%.

Latest developments on Hologic, Inc.

In recent trading, Hologic Inc (NASDAQ:HOLX) saw significant stock price movements, outperforming competitors and gaining traction in the market despite a general market slip. Various investment holdings, including Allspring Global Investments and Allworth Financial LP, have adjusted their shares in Hologic, with Allspring selling a substantial 331,668 shares while Allworth Financial bought 179 shares. Additionally, Bleakley Financial Group has grown their holdings in the company. Analysts have given a consensus recommendation of “hold” for Hologic. The company’s Q2 2025 earnings forecast has been issued by Zacks Research, indicating potential future growth. Furthermore, a partnership with Bayer to advance breast cancer detection with contrast-enhanced mammography underscores Hologic’s commitment to innovative healthcare solutions.

Hologic, Inc. on Smartkarma

Analysts at Baptista Research on Smartkarma are bullish on Hologic Inc, a company focusing on fortifying its market position through innovation and strategic acquisitions. The company recently reported strong fiscal Q1 2024 results, surpassing expectations with total revenue reaching $1.01 billion. Despite facing four fewer selling days compared to the previous year, Hologic achieved a total organic revenue growth of 5.2%, showing resilience in its performance. Adjusting for the fewer selling days, the estimated total company organic revenue growth excluding COVID-19 was in the high single digits.

Furthermore, Baptista Research analysts anticipate continued growth across divisions for Hologic Inc in 2024. The company exceeded analyst expectations in Q4, ending with total revenue of $945.3 million and non-GAAP earnings per share at $0.89. The results showcased a significant 16.7% total organic revenue growth, excluding COVID-19, with double-digit growth in all divisions. Additionally, Hologic allocated substantial capital for share repurchases in Q4 2023 and Q1 2024, demonstrating confidence in its financial position. The analysts’ bullish sentiment reflects optimism towards Hologic’s outlook for sustained growth and strategic initiatives.

A look at Hologic, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Hologic Inc, the company shows a mixed outlook. While it scores high in Momentum with a score of 4, indicating strong market performance, it falls short in Dividend with a score of 1. This suggests that Hologic may not be a top choice for investors seeking income through dividends. However, with moderate scores in Value, Growth, and Resilience, there is potential for long-term growth and stability in the company.

Hologic Inc, a developer and supplier of diagnostic products and medical imaging systems, has a promising long-term outlook based on its Smartkarma Smart Scores. With a strong Momentum score of 4, the company is showing positive market momentum. Although it has lower scores in Dividend, Growth, and Resilience, its core business units focusing on diagnostics, breast health, GYN surgical, and skeletal health position it well for potential growth and success in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma